Latest / Digital Leaders Club By Ingeno / Megan Steck, Director of Manufacturing Engineering at Element Science | MedTech & AI
Transcript
- Guillaume: Welcome to Digital Leaders Club. I am Guillaume Duchano, founder and CEO at Ingenno. This show is built for the leaders running real-world operations on the ones designing, building, and shipping, equipment and connected products that other industries depend on. And today I'm joined by Megan Steck, Director of Manufacturing Engineering at Element Science. Megan, welcome to the show. Megan Steck: Thank you, Guillaume. It's nice to be here. Guillaume: All right, so before we get into the product side, tell us how did you end up in the at the intersection of hardware, software, and because that's where every equipment company lives now, whether they planned it or or not, right? Megan Steck: That's fair. yeah, so I have a mechanical engineering degree. So years ago when I went into the world and said what do I want to do, I started my career in electrosurgical devices. So not really an integrated system, but that was kind of the start. And then from there I went into robotics, so a little bit more of a blend. And then kind of wanted a little different flavor, where you have more of this, you know, machine learning side. So found this product and where I am now today, Element Science, we're developing a wearable defibrillator. So it kind of monitors heart rhythm and then it makes a decision based on our algorithm to deliver therapy in the right kind of abnormal heart rhythm. So that to me was exciting, right? It was kind of a blend of everything that I had done with a little extra, right? It's a it's a unique product. It's a fantastic product. so that was just that was exciting to kind of take one step further in technology. Guillaume: All right. so yes, tell us a bit about the company, the product. So you you you started discussing about it, but yeah, what's the what are the product and what's the scale? Who's your use who are your users? yeah, tell me all about Megan Steck: Yeah. Guillaume: it. Megan Steck: Yeah. So like I mentioned, you know, my in my past, and usually, you know, we're a class three medical device company. So typically your customer is going to be the surgeon or the doctor, or at least, you know, kind of a trained personnel. In our case, obviously we work with physicians and payers, but it really is truly a patient-centric device. It it is something that just a normal, you know, my grandmother, you know, our our peers. We'll take home from the hospital. So it's for people that are at risk of sudden cardiac death. they're prescribed our device and they leave the hospital to go home and, you know, hopefully live a a happy, healthy life. But in this time of risk, as they're being monitored, maybe treated for in the future, an implantable device for long-term care, in that interim, they're using our device, they're interacting with it, they're Replacing, you know, our devices is something that's adhesive, so they'll they'll have to be trained to to use this for a three to six month period. so it's it's interesting to me that you know the the human factor side of it is really important. the the data to make sure our data set is really appropriate for all types of of the population. so that's something we'll continue to improve. But yeah, it's a it's a it's a really great intersection that I think is unique. and then for our support, right? We're we're going directly to the patients when they call and say, I I need help, I have an issue. you know, and when we're saving lives. So there's that element of it's you know, my husband always jokes, Well, at least I'm not saving lives. And that's not something we can say when it comes down to the wire of making decisions. So it's I think it's an important part of our culture too as a company. Guillaume: Right, that that brings meme, I guess, to all of this. Megan Steck: Yeah, yeah, great. Guillaume: yes, so tell me Megan, how do you specifically, you personally, how do you spend your day, your week? you know, not the LinkedIn version, not the official profile Megan Steck: Yeah, yeah. Guillaume: version. So how do you spend your time? Megan Steck: man. It's a it's a nine to five all sorts of everything. there's a lot of sprinkling of firefighting, right? So we have our manufacturing 100% in California. so we run our line and so things come up, you know, parts aren't right, parts didn't come in on time, there's issues with a piece of equipment, so it's a lot of sprinkling of firefighting. There's some programmatic kind of work streams that I lead. So we have a sustaining and scalability program to understand how we get from today to three to five years from now. I run the sales and operational planning. So again, just ensuring that our commercial team and our internal ops team are navigating cohesively. Then a lot of team development stuff, or even just with your peers, or a lot of one-on-ones to ensure you're aligned, development of my my team and my department. So that is kind of a a a big part of each day too. I mean it's the people side, the process side, and then just the make sure nothing goes down, kind of thing too. Guillaume: Right. Megan Steck: Yeah. Guillaume: Right. so tell me what's the difference between let's say your product and let's say the the typical Megan Steck: Mm. Guillaume: similar product that we we had like Megan Steck: That's out there now. Guillaume: years ago, yeah. Megan Steck: Yeah. So the kind of standard of care predicate device that, you know, we we share some similarities from a technology is the Zol life vest. So there is a wearable defibrillator out there. And actually, Kestra is another company that entered the market, but they have similar technologies in the fact that it's truly a vest. the Kestra is almost like a bra, right? That's it's worn across the body. they Can't shower. I mean, technology is great, it's serving a purpose, but where we kind of provide something different, unique, and improved is from the compliance side. So the standard of care now is a vest. You can't shower with it. Sleeping is very difficult. It just is hard for a patient to want to wear it, right? Without feeling inconvenienced or feeling sick. so our device, we hope to take away that part of it that you stick it to your body, it's adhered, you can shower, you can sleep with it, the weight is distributed in a way that hopefully makes it seamless, not perfect. But that is an element that we're really trying to improve that quality of life and that patient experience. So I think that's something that we hope to be, you know, really disruptive and and really make this the new kind of standard moving forward. Guillaume: I so so how how big it is, I I from what you're saying, it seems like it's Megan Steck: Yeah. Guillaume: kinda lightweight, just you kind of f try to forget it, right? Megan Steck: You try, yeah. So it is worn under the clothes on the skin, so at least you can't see it. But it weighs a little under a pound. And that kind of seems like a lot, but the design of this and the construction of our adhesive side bears the weight of that and distributes it. So it and I've worn Guillaume: Mm-hmm. Megan Steck: them a a few over my eleven years of being there. it is it is kind of interesting. You hold it and you're like, This seems heavy, but when you put it on, you know, the design of it really has provided a a seamless in a way wearable product. So there's obviously efforts we want to make with different technological advancements to make it lighter, smaller. that's a that's a gen two. We want to get to the market Guillaume: It's statistic. Megan Steck: as quickly as we could. And we we love that there's still improvements we can make. Guillaume: Nice. what what's the would s you w what would you say is the part of the the product that you're the most proud of at this moment? Megan Steck: Hmm. that's a good one. again, I'm gonna answer this from a more of a manufacturing side. we were thrown a lot of hurdles. I mean, manufacturing in general, right? You're you're sometimes the forgotten one. you know, you're you're taking and implementing a lot of mitigations because you weren't able to to get all the things you wanted in the beginning. So I feel like this the construction and the quality of the product. at this scale. We're not incredibly high volume yet. But I think the team, I'm just very proud of what the team has been able to put out there. the the quality, the the the issues that we've had to resolve to ensure we have this compliant really exceptional product. I think that's been a really good journey and output Guillaume: Nice. Megan Steck: from again Manufacturing team experience, yeah. Guillaume: So typically w for manufacturing company building, let's say, equipment or devices, there's a big part of it that is manual work on the production line, Megan Steck: Mm. Guillaume: right? ideally some part of it can be automated. So where do you stand on that on those fronts? how how much automated your production Megan Steck: Yeah. Guillaume: is right now? Megan Steck: Yeah. So it's very manual. I think there's so many things to say about automation and vertical integration, but we to simplify it, you know, it's it comes down to probably like an ROI. You know, it's it it it is expensive. Two things maybe. The cost of doing it has to be well justified, but also the maturity of your product. Right. If you're going to invest in capital equipment, you hope that you've ironed out enough so that you're not, you know, the next year. changing it so that now you have Guillaume: Have to redo everything, yeah. Megan Steck: to yeah. So there's that balance. I think there's a point where scale, you know, where we are today, it's okay, right? Quality is good. We're able to scale for the next year or two without considerable problems or having, you know, an army on the line. But there is that inflection point where then cost scaling, you know, really isn't as appropriate for such a manual process. so today we're very manual where there's we've taken a risk-based approach. So for things that are critical to the quality of the product and patient care, we've implemented some automation with some of our processes just to alleviate any Guillaume: Mm-hmm. Megan Steck: deep potential defects from operator. So screw fastening, we've done some automation there, adhesive dispensing. And we've tried our best to make you know pokey oak some of our manual fixtures, right? To take away some of the burden from the operator themselves. Guillaume: for this typical this type of equipment, what I hear is typically typically is that you know the expectation, the bar is getting higher and higher because people expect to have highly inter re interoperable devices that connect to various ecosystems. people Megan Steck: Yeah. Guillaume: expect that I wanna have access to my data, I wanna have access Megan Steck: Yeah. Guillaume: to good dashboards. I want to have access to, you know, all sorts of good things that people begin to take for granted because they have that in their other devices, right? Megan Steck: Hm, sure. Guillaume: so tell me, where are you guys at about Megan Steck: Yeah. Guillaume: this? Megan Steck: Addressing it. Yeah, it's a it's a good point, and I think will become even increasingly important to your to your point as we go on in our society today. The the one couple of things we do have. we do have a mobile app for both Android and iPhone. That was something we we kind of incorporated later. We were just iOS, but then we just introduced the capability for Android users. So that app at least gives A different type of user interface for status of the product. It won't tell you all your data. It's not going to give you a full rundown of, you know, your resting heart rate or anything like some of the other products do in the market. But it will give you kind of the the general status, right? We have some training instruction videos there as well to kind of support if they have questions. the other thing we have on the other side for I mean indirectly for the patient, but more so for the physician is we have wear reports. So at a point of time at at the end of the prescription, right, a their physician can look through to really understand where there are different points in this prescription where we see XYZ. That gives the patient and the physician an opportunity to really understand in real time what was happening. Whereas a lot of times you go to the doctor and if you're feeling better when you go, not a lot you can do. So I think that's important, kind of a retrospective. And we are working towards an improvement to an interim wear report. So the ability to kind of see at any date at any sort of point in time what's happening. So I think we're trying to connect maybe not all the data to the patient, but at least again back to their experience, right? That there's that connectivity in terms of the support you'll get from your care team. Guillaume: Nice. you you support your product th with your your your customers, right? So Megan Steck: Mm-hmm. Guillaume: what happens if someone calls, hey, my device doesn't work? do Megan Steck: Mm-hmm. Guillaume: you have like on site technicians that go and help or people have to Megan Steck: Mm. Guillaume: to come to your your facilities or your offices to to to get a or you just send me a new one or how does it work? Megan Steck: It's a little blend of all of that. We do Guillaume: Mm-hmm. Megan Steck: have a customer service team that a lot of times can field these questions directly, or we have a supporting team either, whether it's engineering or quality groups, that can also jump in and support if it becomes very technical. But they have a pretty good script and training that gives immediate feedback to a patient. So they call directly. We also have you know, people in the field on the ground that Right now we don't have the entire geography of the US. So we have a few cities that we're managing because we just launched last year. So we're we're kind of doing this, you know, gradual ramp. So we have multiple people at kind of different levels of support that they give to the patient, but they could go to the person's house, right, and and help them. we also have the ability through either customer service or the field to replace the device. So we have put it on ourselves to replace no more than two days to get a new product to them. So that's something that we, you know, incur those shipping charges, but in a way to make sure that the protection is there for the patient. Yeah. Guillaume: on another topic now. typically connected equipment have different kind of business models. one type is let's say it's a spectrum, I would say, but one end is you pay for the device one time and then not you're on your own, but there's no other fees, and yeah, you have it Megan Steck: Right. Yep. Guillaume: and you use it as is. and the on the other side of the spectrum you have let's say as a service models where device costs nothing or really low price and then you have some sort of subscription or outcome based pricing. So where do you stand on that Megan Steck: Yeah. Guillaume: spectrum? Megan Steck: Yeah. So in general, our kind of payment or or kind of fees incurred by the patient is, I mean, we try to minimize, right, that all this goes through insurance. So we have kind of a reimbursement model. so the cost may vary depending on that. But kind of from a a different business model side, right? We as a business we almost rent out so this. A little nuance here. So our full system that they get, there's kind of different parts to it. For the full prescription length, they will get replacement patches. So something that they'll kind of be a little more disposable side. But the defibrillation unit, that's really our electronics, that's the kind of more integrated system, they keep that with them the whole time. So that unit we almost rent to them. Right. They don't own it. They're expected to give it back, return it. We're almost kind of leasing it, I guess you could say. and that again, just the full system and how many they wear and how long they wear is kind of all based on our reimbursement, based on codes, different codes that that that we can apply to on the claims. So the disposable side on the other side is something that again, they don't pay for out of their, you know, it's not like they pay us directly, but. That's a slightly different model in the fact that again on reimbursement, you're reimbursed for a certain amount that they use every month. So it's it it's really that reimbursement process that is how we as a business are gonna create revenue. so the the the patient themselves, it's a good question of their experience in this, but it'll vary just depending on what coverage they have. Yep. Guillaume: Got it, got it, got it. so what kind of data is your device emitting exactly? So we could think about everything about heart, right? But Megan Steck: Mm-hmm. Guillaume: can you be more precise? Is there anything else, other data that can complement the the heart data and and how you leverage this data to provide a better product or service? Megan Steck: Yeah, yeah. so the types of data we collect now and that it probably as long as we're targeting this specific clinical sector of people at risk of sudden cardiac death that are going home, there's other obviously heart failure and cardiovascular, you know, issues. But the data we collect is related to kind of the you could say the the circuitry of your heart. So transthoracic impedance, ECG signals, so anything related to kind of how that electricity is kind of going through your heart. Also then we can with our machine learning with our algorithm, we have different heart rhythms that we look for and detect. That is what will tell us it's either shockable or not. So VT Guillaume: Mm-hmm. Megan Steck: VF are kind of some of the some of the things you'll hear Asystole is is not good, right? No, no heartline. So I think with that in mind, right, there's specific data that we're looking for with kind of a specific purpose right now. But I think in the long run, those are the main elements. But then there's all sorts of other things that when you extract the data at the end of the products, you know, prescription, there's many other things that in the background it's collecting related to the patient that kind of are this ancillary. components of making decisions on delivering therapy or not. I think with all those data sets, I feel it being really relevant to one, our product development and improvement, right? What are we missing? What could we offer as you know improved features to the patient? Or how does this, you know, provide a gateway into a new clinical sector of cardiovascular, whether it's heart failure Guillaume: Mm. Megan Steck: or inpatient monitoring versus being at home. So I think it provides that. I think the other cool thing, I was just at a women's health horizon summit, and I'm sitting here thinking, okay, maybe there's something different between how you treat different people, whether they have different physiological ailments or just gender or other things, right? That that maybe our data can tell us that. And then maybe we create devices or sell our data, right? To other we kind of want to, you know, the camaraderie of the med tech. industry, you know, is there something that our data can help other inspiring you know, innovators? So I I think there's a lot there to tap Guillaume: Yeah. Megan Steck: into. Guillaume: A are you at a point where you have enough data to see that kind of trend? So people with this kind of Megan Steck: Yeah. Guillaume: traits or demographics or whatever, they have a specific hard profile. I don't know if this is the right term to Megan Steck: Mm-hmm. Guillaume: use, but yeah, are you at a point where you have enough data for this? Megan Steck: I don't know. I mean, I I'm not a statistician or clinical, but I I think we're getting there. Guillaume: Okay. Megan Steck: others may say differently, but you know, we ran a three hundred-ish person clinical trial. That was what we had to do to get approval from the FDA for a PMA. So we have that and then, you know, we were about a year into our commercial. so you have that population, again a a a couple hundred patients. So I I think it's light. maybe it's, you know, we we've learned some things, but more acute. there's some wide QRS complex we call it. So there are some things that are tricking our algorithm, right? And and making us that we're learning from it. We're learning the capability and the the improvement that that we could take on from some of the data we're collecting. So there's sort of those acute learnings. And then I think using the data for a more widespread knowledge is is probably in our future, I would hope, in the next year or two, assuming we can scale and ramp as we'd like. Yeah. Guillaume: Yeah. So data, you know, it's the it's the new gold, it's the new gold mine, Megan Steck: Mm-hmm. Guillaume: right? and you're saying you use AI, and I I guess if you and I'm not sure if you mentioned it, but machine learning to Megan Steck: Mm-hmm. Yep. Guillaume: to interpret the the the signals. What does AI bring that was not possible to do in let's say previous generation of that kind of Megan Steck: Hmm. Hmm. Guillaume: device in the past. Megan Steck: that's a good question. I don't know the the you know, predicate devices I mentioned. I don't know how they trained theirs. I I think Guillaume: Mm-hmm. Megan Steck: the probably simplest answer I have because I don't know, I don't know all of that. I would say is just the amount of data you get every year. You know, like you just have a broader, more mature data set to learn from. so I think that's probably something we gained that. you know, coming out at a different year versus the other device started at 20 years ago. I'm sure they've been retraining as they go, but that was maybe a benefit we had is just a broader data set, more data points to really fine-tune our algorithm. but yeah, I don't I don't know. Maybe there's other other features that we've been able to do and that, you know, there's probably someone on our algorithm team that speaks to it better. Yeah. Guillaume: Right. But I was thinking maybe naively in the past there was no AI. So it was maybe a like a simple approach where the the the optim the let's say the the the most naive way of saying that is okay, there's no hard signal, so let's just send some maybe it's just that, but I I I I don't know. I I I'm not super familiar with that. Megan Steck: Yeah. Yeah. Yeah. Right. Right. Right. Yeah. I think the like many years ago, like when you only had pacemakers and I C D's, right, that was truly looking for just a more binary. Like it's not monitoring, it's not making decisions. It's just seeing something. It's more electrical. Seeing something, deliver therapy. It's like a closed loop, but not in a in this sort of sophisticated way. Yeah. Guillaume: so you're in engineering. engineering can mean you know physical stuff, but it can also mean software engineering. So how much let's say physical versus digital engineering is happening at your company? Megan Steck: There's a blend. Our group mainly works on the physical engineering side. So with more of the mechanical, electrical teams from a hardware side. But, you know, it's our it's probably more of our test systems that then you get the true integration of our firmware, software, kind of how those worlds collide. So it's probably more in our automated testing of our product that there's more hands-on from at least our group, but as a company, there's There's a significant amount of kind of that. you know, our algorithm group, software, firmware coming together to ensure that the product is there's continuous improvement, there's monitoring. Yes, that's a that's a around the clock, especially now when, you know, you're scaling and you want to make sure that this product delivers kind of the utmost quality to the patient. Yep. Guillaume: So if you could fix one thing about your product or yeah, how you operate in your business, something that's been maybe on the roadmap for a while but keeps getting pushed, what would that be? Megan Steck: There's a few again, I've been there eleven years. There's probably a lot that, you know, you you there's trade-offs. There's a right time to do things, you right size, have to prioritize. I think the not sexy answer is our risk management. there's some fundamental things, especially about medical device, I'm sure other industries too, but there's fundamentals that just ensure the day-to-day efficiencies are as seamless as possible. Right. There's kind of smart people can work really hard. We have a ton of those. They can put in the effort and they can be successful. But how that effort is conducted, the time it takes, it's I think we have some fundamentals. It just takes time, right? It's not an easy thing. We have nothing wrong with what we're doing. There's just an improvement to make work more scalable. And I think as a process-driven person, even on the product side, right, to ensure that we can get things to the market to the patient sooner, if you can take away those inefficiencies, whether through fundamental quality system improvements or either, you know, our our our best friend, you know, AI, I do think that's gonna be instrumental for us to push product improvements out, to reduce cost, to improve efficiencies, it it's really comes down to just fundamentally how you're able to do the work. And I think taking guesswork out, taking subjectivity out, taking lengthy, you know, two hour meetings up to your VP and COO, if you can reduce that to make teams more autonomous, I think that's giving them a better framework. I would, I would just love to see us get there. And I think we're at Guillaume: Can you give? Megan Steck: a transition in the company where that's gonna be more important than it was, you know, five years ago. Guillaume: Can you give a a a concrete example of where you s see improving could have a a good impact on your yeah, overall efficiency, reduce let's say errors or Megan Steck: Mm. Guillaume: yeah, making make people faster. Megan Steck: Yeah, let's see. There's there's a variety from our supply chain to internal. one thing this is this is actually a funny example because it's not the most critical. It's not it's not going to give us the greatest impact, but it's an example of the inefficiencies that you know we have a sponge in our product and it seems simple. It seems, you know, we're just trying to find an alternate supplier and reduce cost, you know, and in this this whole scaling effort. And we we we kind of run around trying to understand there's different perspectives on how to qualify. you know, down to requirements and risk, and you know, do you even need packaging, do you not need packaging? Is there a bio burden risk? There's all these things that just float in the air. And I point to the fact that if we had a framework, right, of of how to navigate these questions, that then these decisions could have been made, you know, months ago, versus going around in circles of a lot of opinions. You have, you know, better guidelines, better principles. Because the the example is just something this simple, if you can't make Guillaume: Yeah. Megan Steck: decisions on, how do you do the the more critical ones, right? The more criticality components or suppliers. Guillaume: If you change something like this, do you need to to go through another, let's say, compliance process with the Megan Steck: Mm. Hmm. Guillaume: the FDA or maybe not that one, but some others, I guess. Megan Steck: It kind of depends. So the risk management in general, you know, we we've we are registered, we've gotten our PMA approval, but you know, the FDA will always knock on your door at some point. You never know. So Guillaume: Mm-hmm. Megan Steck: you always wanna be ready. I think risk management is something that they basically point to all the time when they go to audit or, you know, through your process, it's kind of like that anchoring system. If you make changes to it, it just depends on the kind of changes, right? If it's an overhaul, maybe you're letting them know. But the changes to your product, it it's every little change we make, we basically scrutinize to say, you know, does it have to go through, you know, the the whole process up to the FDA or not? So it's it's a different industry to work in to make changes, to be innovative, because it's not as quick. Can't get as creative as maybe you know you'd like to. Guillaume: Hmm. Where do you see is the biggest opportunity for organization like yours that, Megan Steck: Mm. Guillaume: you know, build medical devices, connected medical devices, to differentiate over the next, let's say, five years? Megan Steck: Biggest opportunity for like to improve. mm, come. Guillaume: To to differentiate, to to to win the market, to to be the the the the example everyone talks about, right? Megan Steck: Yeah. I think there's a few different areas. I mean we we touch a lot on our device primarily addressing a patient experience improvement. So I think if we can make it lighter, if Guillaume: Mm-hmm. Megan Steck: we can make it smaller, if we can provide like we were talking about earlier, better live feedback to the patient or something that gives them clarity in their condition, stuff at their fingertips. if they could even you know use that, then integrate it with their other devices, right? It's it's a tricky thing with us. We can't talk to our device for many reasons, cybersecurity and all of that, but is there some way to integrate it with other you know, products or just to make Guillaume: Mm-hmm. Megan Steck: them feel like this is part of their day to day and not, you know, just a medical device. It's actually something that is is is more part of the day, but in a good healthy way. maybe there's an opportunity there, right? That to make it more integrated. and then just you know giving them that feedback, right? Is there something that we can simplify the process of even how this device is used? that doesn't require, you know, laborious training or hours for them to, you Guillaume: Mm-hmm. Megan Steck: know, do this step, then this step, then this step. So I think there's there's that element. yeah. So I I think it's it's really ensuring that this is something physicians want to prescribe over and over again. And that goes down to are the patients wearing it? Are they, Guillaume: Mm-hmm. Megan Steck: you know, is it saving their life? so I think that could be an element of just the the data, how it How it supports them and the physicians. Guillaume: right. and and how do you see because from what I understand from what you you you said from since we beginning our we began our conversation is the way your product gets into the hand of of your end customer, it's through the physicians, right? They don't they they don't research that by themselves, right? They Megan Steck: Mm-hmm. Yes. They can't go and get it themselves. Not not yet. I had an interesting conversation with someone that's like, hey, I'm a runner and I want to make sure, you know, that I'm protected. You hear stories. And I think it's very fair that I don't it'd be expensive for somebody, but that goes back to access and how you make this cheaper and design it for Guillaume: Mm-hmm. Megan Steck: scale so that you can afford it to a broader population. But maybe there's that day, right? Where it's Different people can wear it even if they don't have a condition that's been diagnosed. That'd be nice. Yeah. Guillaume: Hmm. what would be a decision that you have made, let's say in a couple last year that was really a win for you, your Megan Steck: Mm-hmm. Guillaume: organization? About technology, about maybe a partner or about yeah, how you do s how you do your thing your engineering. Megan Steck: Yeah. Mm. A win. We've had lots of little wins. Trying to think at a larger level. It's a good question. I'd say we this may sound trivial, but like I said, we we've been operating like a startup for many years and it's been wonderful. It's gotten us here. We have a great product. But recently we've really aligned on kind of this, and you can always improve it, but I truly think we've aligned on more of this, you know, framework or d vision of a true North. You know, we we have goals that matter. I think collectively at the end of the day, for the most part, you know, people understand are we winning, are we losing? I think that's from a culture standpoint really important. I'm I'm really big on on just people knowing what they contribute and the importance of it. That's what's gonna make the product and the company successful and therefore deliver, you know, the the best to a patient. But I think that framework of aligning everyone on what's important because you could go so many different directions and departments all have their own idea of what should we do what we should do, what we shouldn't. I think that'll be really that that's huge for us now. And I think it'll really take us into the next few years with better alignment to reduce some of the noise that we can focus on what's really most important to the product and and keep us then ahead of the game. You know, there's There will always be other competitors and you think you've got something novel and then all of a sudden, you know. so I think that's important to keep people aligned and focused and creating that pathway for success. So I think that'll be instrumental for us. Yeah. Guillaume: D do you use a framework like OKRs or something like that? Or you have your own your own let's say on ground tools? Megan Steck: tools and yeah. That would be one thing I would say we could improve on if we talk about then the opportunity here. You know, we have a little bit of a scattered collection of systems, whether it's Guillaume: Mm-hmm. Megan Steck: you know, where we have goals, where we have our project management, program management. it's a it's a little scattered. I mean we're only 83 people or something. So you can navigate, but I think that'll be that'll be a big one for us to move to a little bit more of a sophisticated version of our system, business systems. Yeah. Guillaume: All right. A and we talked about a a decision that was a win. Could you name let's say a decision that you would take back if you could? Megan Steck: Hmm. what to say I could take back. I'd say maybe not take back, but a decision that I think has been difficult that we haven't made and of answering it that way is you know, we we're having it's it's everything we do is a little bit of a balancing act, right? There's not Two inputs, there's usually five, and it gets really complicated. and I think we're at again this inflection point of needing to scale and think about the the three to five year plan versus tomorrow and having a little bit of a a tough time deciding how to prioritize that next step in terms of scaling. you know, do we try to Fold in our Gen 2 with our new supply chain? Do we just lift and shift and find the new supplier, fix things later? There's all these caveats. And I I think that, not that a decision has been entirely made, but that process has been difficult. and probably will continue to be, but I I think that's where we're gonna have a little bit of the difficulty as we move forward, which is natural for where we are, but I think, you know, offshoring, near shoring, all those kind of conversations as well. Guillaume: Yeah, I can I can relate because there's so many things that you you think we need to do that, but you can't do them all, right? You you have to choose and it's Megan Steck: Yeah. Yeah, exactly. Yeah. Guillaume: there's no well, sometimes there is, but most of the time there's no perfect answer to that, right? So you you need to pick yes, Megan Steck: Correct. Yep. The lining on the trade offs. Guillaume: exactly. That's that's hard. I I can understand that. Yeah, yeah. Megan Steck: It's very hard. It's yeah. So I think it's good. It's a healthy friction. It's needed. It's just at the end of the day, right? Where do we stand to at least say, Yep, we looked at all this and we know it's not gonna be great, but here's, you know, kind of the path forward, here's the sort of the the statement of work now for the next future. Yep. Guillaume: All right, so for another let's say medical equipment leader, like a C or CTO or someone in your role in engineering who's listening to us. And and they wonder how to leverage technology, leverage AI, and and and be successful in their field. and Megan Steck: sí. Guillaume: wondering where to start. So what would be your harness advice? Megan Steck: Yeah, I think I feel like this has just been, I mean, for a while now being discussed, but it's the actual implementation that then people truly think how how there's theories and there's ideas. But so I've I've thought a lot about it and I would answer it, you know, again in in the in the vein of manufacturing and not maybe necessarily the the product. but yeah, generally how I think about it. As an advancement, as a value add. is in terms of talked about efficiencies. To me, that's the big thing is right now industries, manufacturing, will struggle with creativity and speed. so I think if you're implementing and integrating AI in an appropriate way to reduce inefficiencies to you know I'm kind of indirectly talking about how to impact product, but if you are able to curb some of the inefficiencies that are requiring, you know A significant headcount or facility footprint, and therefore the spend and the overhead of the company is going into that, you aren't as able to pump that back into innovation and the product and the hiring, maybe on the engineering side or the upskilling of people. So I think indirectly there's an opportunity for innovation and improvement to product if you cut through the kind of the lower hanging fruit, you know, like improving. Workflows in your ERP. Now, obviously people pay a ton of money for ERP systems and some of those, but is there a cheaper way to do that, right? That's also more flexible and real time, right? 'Cause those systems take a long time to to implement and cost. So you have something at your fingertips that maybe is a little more nimble, easier for people to also navigate. And just those little things, right? Of just material movement. These like again, this is my six sigma head of just you take away all those things. One in themselves isn't maybe as important, but you do this collectively. And it really, really will save time, money, and just effort. And even having those conversations as CTOs, as COOs, you can really focus on what's truly important about the product. Put the effort and attention there, because you've reduced the other noise. so I I think it's huge if done right and if done effectively, cause it it's there's so much out there. I think that's where I struggle of just which one do you even do? And then you just get the paralysis of do we don't do anything. Guillaume: Yeah, we go back to it's it's a big world of compromises. But I hear you, there's a compound effect, right? you you Megan Steck: Mm-hmm. Guillaume: add one and then you have some improvement, but it's the accumulation of all those optimizations that that will pay off over time. Megan Steck: Yes. Yeah. Yep. Guillaume: all right. so Megan, we are almost at time, but before I let you go, Quick lightning round of questions. first thing Megan Steck: Okay. Guillaume: that comes to mind, no overthinking. You have the right to pass, but not too much. Please. so Megan Steck: Yeah. Guillaume: what would be in your opinion the most overrated thing in let's say medical devices or connected products today? Megan Steck: The most overrated. I'd say some of some of the the the shiny things like apps, you know, a lot of features that are or seem really nice to have and buzzwords, all that. Kind of over that Guillaume: right. one piece of technology in your product that you're genuinely proud of. Megan Steck: One piece of technology or something Guillaume: Or or aspect, let's say. Megan Steck: generally proud of. I I think we did a novel thing. This is slight detail, but we we did a really novel thing with our kind of this electromechanical backplane that was very unique to integrate all of our circuitry through these flexible modules. we really had to rethink how to use these, you know. kind of off-the-shelf components that are not typically used in this application and and it it worked. I mean it was it was huge. This was a redesign from our first gen product that we planned to go to the field with. And then we we diverted changed courses because it wasn't economical. And the engineers came up with this just really sleek, unique design to kind of integrate five modules together, being flexible, being you know navigating through fatigue. It was yeah, I think that's pretty novel about our product. Guillaume: Nice, nice. if what what what trade show do you guys go to? Megan Steck: that's a good question. probably what the sales team could answer and not me. I know they they talk about it. Different conferences for cardiovascular, right, where other products are being showcased like ours. I don't remember the names. Guillaume: That's fine. You can pass one. It's okay. Megan Steck: There you go. Okay. Guillaume: so what do great medical or maybe in general equipment companies do that average ones don't? Megan Steck: Hmm. I think they think about long term, right? they and when I say that, you know, they kind of they look at the space for technology opportunities, for things that even if it's not a right now to implement, you're kind of thinking in the future, right? You're you're you're breaking down what could be a problem. three to five years, right? And at least building some of that knowledge and maybe even mitigation plans in now. So that you're not sitting on a bunch of carrying costs and inventory and things that, you know, are really hard to navigate once you're you're scaling in in commercial. So I think it's that foresight. Guillaume: Nice. last but not least, Megan, if you were not in engineering, in a medical device company, manufacturing company, I mean, what would you be doing? Megan Steck: What I do. no. I this is a tough one. I'll tell you what I wish. Yeah, Guillaume: Yeah. Megan Steck: if money didn't matter and I didn't you know, yeah, I feed off Guillaume: Yeah, you you can dream, whatever. Megan Steck: stress, but if I didn't, because I do love stress, I think I would I would kind of open some non profit and you know, I'm a big proponent of kids and health and education. So I feel like I'd try to find some way to create, you know, a community space and an organization that provides help for kids, kids that, you know, need a little extra guidance and direction. Yeah, completely different. Guillaume: Nice. Yeah, that's that was the angle of the question. All right, Megan Steg, this was a genuinely great conversation. Thank you so much. really appreciate Megan Steck: Yeah, thank you. Guillaume: how candid you were about what's actually happening at your company and how you work. and this is exactly what this show is for, right? So if our listener want to hear about you, what you're building, where can they where can they find you? Megan Steck: Yeah, I mean I'm always open on LinkedIn and and also our website if you want to learn more about the product is just element science dot com. So check either of those out and hopefully you'll just see it around the community and you can ask one of our patients too. Guillaume: All right, all right. Thank you very much for listening to Digital Leaders Club. if you're an equipment leader, just like Megan, dealing with any of the challenges we've talked today, I would love to continue this conversation. You can find us at ingeno dot ca. until next time. Thanks again, Megan. Megan Steck: Thank you very much.